1.42%)
-14.97%)
Back
10 MIN READ
MEDFORD, Ore., March 28, 2023 /CNW/ – Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a craft cannabis company operating in Oregon and Michigan, is pleased to report its fiscal first quarter 2023 results for the three months ended January 31, 2023. All financial information is provided in U.S. dollars unless otherwise indicated.
First Quarter 2023 Financial Summary ($USD Millions)
First Quarter 2023 Summary | Q1 2023 | Q1 2022 | +/- % |
Revenue | 4.5 | 3.7 | +21 % |
aEBITDA | 1.3 | 1.0 | +33 % |
aEBITDA % | 29.5 % | 26.9 % | +2.6 % |
OCF (Before Changes in WC) | 1.3 | 0.5 | +176 % |
OCF % | 28.4 % | 12.5 % | +15.9 % |
Management Commentary
“We continue to demonstrate our operating abilities by generating substantial free cash flow margins while operating in extremely competitive markets. Our financial results for Q1 2023 were improved from Q4 2022 due to of our continued pursuit of operating efficiencies, and a modest increase in average wholesale pricing in Oregon,” said Obie Strickler, CEO of Grown Rogue.
“As we move forward, we are proactively ramping up our genetics programs in both Oregon and Michigan to make sure we stay on the front line of delivering industry-leading quality to our consumers. We believe that our philosophy and practice of constant iteration and improvement will engender more customer trust and deepen the relationship we have with our existing fans,” Mr. Strickler continued.
“Regarding capital allocation, we continue to focus on producing free cash flow to best position ourselves to meet our balance sheet obligations while being prepared for new market opportunities, using only a modest amount on increased working capital. With our internal cash generation and the recent $2M convertible debenture capital raise, we feel confident in our ability to take advantage of high-quality opportunities as they arise.
I want to thank the entire Grown Rogue team for their continued efforts and look forward to updating investors on our new market efforts in due course.”
Oregon Market Highlights ($USD Millions)
Oregon | Q1 2023 | Q1 2022 | +/- % |
Revenue | 2.0 | 1.4 | +41 % |
aEBITDA | 0.7 | 0.4 | +79 % |
aEBITDA Margin % | 37.4 % | 29.4 % | +8 % |
- #1 Flower brand for seven consecutive quarters, according to LeafLink’s MarketScape data
- Grown Rogue increased Oregon sungrown capacity with a lease option of 35 additional acres in Oregon’s Rogue Valley, that includes an addition cultivation license
- Focusing on increasing market share by launching craft pre-roll products in Q2-Q3 2023
Michigan Market Highlights ($USD Millions)
Michigan | Q1 2023 | Q1 2022 | +/- % |
Revenue | 2.6 | 2.3 | +10 % |
aEBITDA | 1.1 | 1.0 | +10 % |
aEBITDA Margin % | 43.6 % | 43.5 % | +0.1 % |
- Grown Rogue exercised its option and acquired 87% of Canopy Management, LLC resulting in its controlling interest in Golden Harvests, LLC
- Launching strain specific packaging in Q2-Q3 2023 which has garnered significant interest from customers
Michigan operations are through Golden Harvests, LLC.
Financial Statements and aEBITDA reconciliation
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | January 31, 2023 | October 31, 2022 |
$ | $ | |
ASSETS | ||
Current assets | ||
Cash and cash equivalents | 3,488,046 | 1,582,384 |
Accounts receivable (Note 18) | 1,276,546 | 1,643,959 |
Biological assets (Note 3) | 1,434,080 | 1,199,519 |
Inventory (Note 4) | 3,614,247 | 3,131,877 |
Prepaid expenses and other assets | 362,345 | 352,274 |
Total current assets | 10,175,264 | 7,910,013 |
Property and equipment (Note 8) | 7,880,350 | 7,734,901 |
Intangible assets and goodwill (Note 9) | 725,668 | 725,668 |
TOTAL ASSETS | 18,781,282 | 16,370,582 |
LIABILITIES | ||
Current liabilities | ||
Accounts payable and accrued liabilities | 1,664,264 | 1,821,875 |
Current portion of lease liabilities (Note 7) | 1,280,277 | 1,025,373 |
Current portion of long-term debt (Note 10) | 1,956,428 | 1,769,600 |
Current portion of convertible debentures (Note 11) | 194,426 | – |
Business acquisition consideration payable (Note 5) | 360,000 | 360,000 |
Unearned revenue | 52,318 | 28,024 |
Derivative liability (Note 11.1) | 721,849 | – |
Income tax | 311,032 | 311,032 |
Total current liabilities | 6,540,594 | 5,315,904 |
Lease liabilities (Note 7) | 1,251,759 | 1,275,756 |
Long-term debt (Note 10) | 339,664 | 839,222 |
Convertible debentures (Note 11) | 1,062,828 | – |
TOTAL LIABILITIES | 9,194,845 | 7,430,882 |
EQUITY | ||
Share capital (Note 12) | 21,894,633 | 21,858,827 |
Shares issuable (Note 12) | – | 35,806 |
Contributed surplus (Notes 13, 14) | 6,560,714 | 6,505,092 |
Accumulated other comprehensive loss | (111,035) | (109,613) |
Accumulated deficit | (19,531,463) | (21,356,891) |
Equity attributable to shareholders | 8,812,849 | 6,933,221 |
Non-controlling interests (Note 22) | 773,588 | 2,006,479 |
TOTAL EQUITY | 9,586,437 | 8,939,700 |
TOTAL LIABILITIES AND EQUITY | 18,781,282 | 16,370,582 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | Three months ended January 31, | |
2023 | 2022 | |
$ | $ | |
Revenue | ||
Product sales | 4,530,540 | 3,732,713 |
Total revenue | 4,530,540 | 3,732,713 |
Cost of goods sold | ||
Cost of finished cannabis inventory sold (Note 4) | (2,037,281) | (1,699,026) |
Gross profit, excluding fair value items | 2,493,259 | 2,033,687 |
Realized fair value amounts in inventory sold | (606,715) | (1,010,478) |
Unrealized fair value gain on growth of biological assets | 630,872 | 1,289,514 |
Gross profit | 2,517,416 | 2,312,723 |
Expenses | ||
Accretion expense | 164,108 | 151,687 |
Amortization of property and equipment | 115,639 | 52,010 |
General and administrative | 1,535,242 | 1,603,926 |
Share-based compensation | 55,622 | 18,487 |
Total expenses | 1,870,611 | 1,826,110 |
Income from operations | 646,805 | 486,613 |
Other income and (expense) | ||
Interest expense | (99,504) | (114,660) |
Other income (expense) | 223,774 | (5,440) |
Unrealized loss on marketable securities | – | (167,804) |
Unrealized gain on derivative liability | 64,360 | – |
Loss on disposal of property and equipment | (168,144) | (6,250) |
Gain from operations before income tax | 667,291 | 192,459 |
Income tax | (74,754) | (37,018) |
Net income | 592,537 | 155,441 |
Other comprehensive income (items that may be subsequently reclassified to profit & loss) | ||
Currency translation loss | (1,422) | (13,658) |
Total comprehensive income | 591,115 | 141,783 |
Gain per share attributable to owners of the parent – basic and diluted | 0.01 | 0.00 |
Weighted average shares outstanding – basic and diluted | 169,193,812 | 164,976,815 |
Net income (loss) for the period attributable to: | ||
Non-controlling interest | (339,408) | 564,607 |
Shareholders | 931,945 | (409,166) |
Net income | 592,537 | 155,441 |
Comprehensive income (loss) for the period attributable to: | ||
Non-controlling interest | (339,408) | 564,607 |
Shareholders | 930,523 | (422,824) |
Total comprehensive income | 591,115 | 141,783 |
CONSOLIDATED CASH FLOW STATEMENTS | Three months ended January 31, | |
2023 | 2022 | |
$ | $ | |
Operating activities | ||
Net income | 592,537 | 155,441 |
Adjustments for non-cash items in net income: | ||
Amortization of property and equipment | 115,639 | 52,010 |
Amortization of property and equipment included in costs of inventory sold | 276,562 | 147,463 |
Unrealized gain on changes in fair value of biological assets | (630,872) | (1,289,514) |
Changes in fair value of inventory sold | 606,715 | 1,010,478 |
Share-based compensation | – | 7,499 |
Stock option expense | 55,622 | 54,797 |
Accretion expense | 164,108 | 151,685 |
Loss on disposal of property & equipment | 168,144 | 6,250 |
Unrealized loss on marketable securities | – | 167,804 |
Gain on fair value of derivative liability | (64,360) | – |
Effects of foreign exchange | 933 | 1,807 |
1,285,028 | 465,720 | |
Changes in non-cash working capital (Note 15) | (419,285) | (389,648) |
Net cash provided by operating activities | 865,743 | 76,072 |
Investing activities | ||
Purchase of property and equipment and intangibles | (36,378) | (574,595) |
Payments of acquisition payable | – | (2,000) |
Net cash used in investing activities | (36,378) | (576,595) |
Financing activities | ||
Proceeds from convertible debentures | 2,000,000 | – |
Proceeds from long-term debt | – | 100,000 |
Proceeds from private placement | – | 1,300,000 |
Repayment of long-term debt | (420,730) | (218,710) |
Repayment of convertible debentures | (15,000) | – |
Payments of lease principal | (487,973) | (186,922) |
Net cash provided by financing activities | 1,076,297 | 944,368 |
Change in cash | 1,905,662 | 493,845 |
Cash balance, beginning | 1,582,384 | 1,114,033 |
Cash balance, ending | 3,488,046 | 1,607,878 |
SEGMENTED aEBITDA – THREE MONTHS ENDED JANUARY 31, 2023 | ||||
Oregon | Michigan | Corporate | Consolidated | |
Sales revenues | 1,955,720 | 2,574,820 | – | 4,530,540 |
Costs of goods sold, excluding fair value (“FV“) adjustments | (936,086) | (1,101,195) | – | (2,037,281) |
Gross profit before fair value adjustments | 1,019,634 | 1,473,625 | – | 2,493,259 |
Net fair value adjustments | (78,012) | 102,169 | – | 24,157 |
Gross profit | 941,622 | 1,575,794 | – | 2,517,416 |
Operating expenses: | ||||
General and administration | 494,918 | 474,928 | 565,396 | 1,535,242 |
Depreciation and amortization | 30,939 | 60,839 | 23,861 | 115,639 |
Share based compensation | – | – | 55,622 | 55,622 |
Other income and expense: | ||||
Loss on sale of assets | (168,144) | – | – | (168,144) |
Interest and accretion | (75,187) | (60,685) | (127,740) | (263,612) |
Unrealized loss on derivative liability | – | – | 64,360 | 64,360 |
Other income and expense | 222,220 | – | 1,554 | 223,774 |
Net income (loss) before income tax | 394,654 | 979,342 | (706,705) | 667,291 |
Income tax | 24,754 | 50,000 | – | 74,754 |
Net income after tax | 369,900 | 929,342 | (706,705) | 592,537 |
Add back (deduct) from net income after tax: | ||||
Net FV adjustments in costs of goods sold | 78,012 | (102,169) | – | (24,157) |
Amortization of property & equipment included in cost of sales | 152,443 | 124,119 | – | 276,562 |
Interest and accretion expense | 75,187 | 60,685 | 127,740 | 263,612 |
Amortization of property and equipment | 30,939 | 60,839 | 23,861 | 115,639 |
Share-based compensation | – | – | 55,622 | 55,622 |
Unrealized gain on derivative liability | – | – | (64,360) | (64,360) |
Income tax expense | 24,754 | 50,000 | – | 74,754 |
EBITDA | 731,235 | 1,122,816 | (563,842) | 1,290,209 |
Add back to EBITDA: | ||||
Compliance costs | – | – | 17,997 | 17,997 |
Costs associated with acquisition of Golden Harvests | – | – | 30,000 | 30,000 |
aEBITDA | 731,235 | 1,122,816 | (515,845) | 1,338,206 |
aEBITDA margin % | 37.4 % | 43.6 % | — | 29.5 % |
NOTES: | |
1. | The Company’s “Free cash flow” metric is defined by cash flow from operations minus capital expenditures. |
2. | The Company’s “aEBITDA,” or “Adjusted EBITDA,” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines “EBITDA” as the Company’s net income or loss for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities, the effects of fair-value accounting for biological assets and inventory, as well as other non-cash items and items not representative of operational performance as reported in net income (loss). Adjusted EBITDA is defined as EBITDA adjusted for the impact of various significant or unusual transactions. The Company believes that this is a useful metric to evaluate its operating performance. |
NON-IFRS FINANCIAL MEASURES
EBITDA and aEBITDA are non-IFRS measures and do not have standardized definitions under IFRS. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. Accordingly, the following information provides reconciliations of the supplemental non-IFRS financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.
About Grown Rogue
Grown Rogue International (CSE: GRIN | OTC: GRUSF) is a craft cannabis company focused on delighting customers with premium flower and flower-derived products at fair prices. Our roots are in Southern Oregon where we have demonstrated our capabilities in the highly competitive and discerning Oregon market and, more recently, we successfully expanded our platform to Michigan. We combine our passion for product and value with a disciplined approach to growth, prioritizing profitability and return on capital. Our strategy is to pursue capital efficient methods to expand into new markets, bringing our craft quality and value to more consumers. We also continue to make modest investments to improve our outdoor craft cultivation capabilities in preparation for eventual interstate commerce.
FORWARD-LOOKING STATEMENTS
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Company’s public disclosure documents filed on Sedar.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States through its indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activities are currently illegal under United Statesfederal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are disclosed in the Company’s Listing Statement filed on its issuer profile on SEDAR at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
SOURCE Grown Rogue International Inc.
For further information: For further information on Grown Rogue International please visit www.grownrogue.com or contact: Obie Strickler, Chief Executive Officer, Obie@grownrogue.com; Jakob Iotte, Director of Business Development and IR, Jakeiotte@grownrogue.com, (458) 226-2100
All good -- no spamming here.
Get the Latest Cannabis News & Stock Picks.
Comments